FDA Needs Three-Month Extension to Review Ironwood Drug

April 24, 2012
Ironwood Pharmaceuticals and New York’s Forest Laboratories today announced that the U.S. Food and Drug Administration has notified both companies that it requires a three-month extension to complete its review of data supporting a new drug application for the investigational drug linaclotide.
Boston Herald